Download Image
    
Share
  
Post
Belnacasan for COVID-19
1 study with 31 patients
No significant improvements are seen in meta analysis to date.
COVID-19 Belnacasan studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -34% RCTs -34% Early -34% Favorsbelnacasan Favorscontrol
Oct 11
2022
 Wortmann et al., NCT05164120 A Proof of Concept, Randomized, Double-blind, Placebo-controlled Trial of Orally Administered Belnacasan Tablets for the Treatment of Mild to Moderate COVID-19
34% slower recovery (p=0.29). RCT 40 outpatients in the USA, showing no significant difference in recovery with belnacasan treatment.